Successful unconventional precision treatment of inflammatory hormone receptor-positive breast cancer guided by molecular profiling
Last Updated: Friday, July 17, 2026
A case study of a patient with HR+ HER2- breast cancer with a MammaPrint gene signature indicating a very high risk of recurrence. The patient was treated with a triple-negative breast cancer protocol, and she achieved a complete response. She remains disease free after 2 years, with ongoing follow-up.